From the Research
The recommended dosage of Dufastone (dydrogesterone) for treating uterine bleeding is typically 10 mg twice daily for 5-10 days, starting on day 16 of the menstrual cycle. For acute episodes of abnormal uterine bleeding, treatment may begin with 10 mg twice daily for 5-7 days. After bleeding stops, the dose is often continued for an additional 1-2 cycles to establish regular patterns. Dufastone works by stabilizing the endometrial lining and counteracting estrogen's proliferative effects on the uterus, which helps control excessive bleeding. The medication is a synthetic progestogen that mimics natural progesterone but has enhanced bioavailability when taken orally. Patients should take the medication with food to enhance absorption and minimize potential side effects like nausea. If bleeding persists despite treatment, medical evaluation is necessary as this could indicate underlying conditions requiring different management approaches. Treatment duration should be individualized based on response and the specific bleeding disorder being treated, as noted in studies such as 1. However, it's crucial to consider the most recent and highest quality evidence available, which may not directly mention Dufastone but discusses the management of abnormal uterine bleeding, as seen in 2 and 3. Given the information provided and prioritizing morbidity, mortality, and quality of life, the dosage of Dufastone should be tailored to the individual patient's needs and response to treatment. Key considerations include:
- Starting dose and duration based on the severity of bleeding and patient history
- Potential side effects and how to minimize them
- The importance of follow-up to assess treatment efficacy and adjust the treatment plan as necessary
- Considering alternative treatments if Dufastone is not effective, as discussed in studies like 4 and 5. In clinical practice, the decision to use Dufastone and the dosage regimen should be guided by the most current clinical guidelines and the patient's specific clinical scenario, always prioritizing outcomes related to morbidity, mortality, and quality of life.